Last reviewed · How we verify
NCT03888911
Benefit and Tolerability of IQP-LU-104 in Weight Loss
NA trial testing High dose IQP-LU-104 (5120mg) in Overweight in 108 participants. Completed in 21 November 2019.
21 November 2019
Quick facts
| Lead sponsor | InQpharm Group |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 108 |
| Start date | 5 March 2019 |
| Primary completion | 21 November 2019 |
| Estimated completion | 21 November 2019 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- High dose IQP-LU-104 (5120mg)
- Low dose IQP-LU-104 (2560mg)
- Placebo
Conditions studied
- Overweight — all drugs for Overweight →
- Obesity — all drugs for Obesity →
Sponsor
InQpharm Group
Who can join
Adults 18 to 65, any sex, with Overweight or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to evaluate the benefit and tolerability of two dosages of IQP-LU-104 (5120mg and 2560mg daily) in reducing body weight in overweight and moderately obese subjects
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Flaxseed Mucilage (IQP-LU-104) Reduces Body Weight in Overweight and Moderately Obese Individuals in a 12-week, Three-Arm, Double-Blind, Randomized, and Placebo-Controlled Clinical Study.
Bongartz U, Hochmann U, Grube B, Uebelhack R, et al · · 2022 · cited 8× · PMID 35130547 · DOI 10.1159/000522082
Verify or expand the search:
- PubMed search for NCT03888911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Overweight
Currently open trials in the same condition.
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07472881 — Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women · NA · recruiting
- NCT07465965 — A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults · Phase 1 · recruiting
- NCT07407348 — A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the · Phase 1 · recruiting
- NCT07400653 — A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) · Phase 3 · recruiting
Other InQpharm Group trials
Trials by the same sponsor.
- NCT03232255 — Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity · NA · completed
- NCT03227276 — Efficacy and Safety of Litramine in 1 Year Weight Loss Study · NA · completed
- NCT03058367 — Benefit and Tolerability of IQP-AE-103 in Weight Loss · NA · completed
- NCT03114696 — Benefit of IQP-AO-101 for Sleep · NA · completed
- NCT02871362 — Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03888911 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by InQpharm Group
- Last refreshed: 3 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03888911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing